exhibit 10. 1 first amendment to license agreement between novartis pharma ag and allarity therapeutics europe aps ( formerly known as oncology venture aps ) effective as of march 30, 2022 first amendment to license agreement this first amendment to license agreement ( the “ amendment ” ) is made as of the 30th day of march, 2022 ( “ effective date ” ), by and between novartis pharma ag, a company organized under the laws of switzerland and located at lichtstrasse 35, 4056 basel, switzerland ( “ novartis ” ), and allarity therapeutics europe aps ( formerly known as oncology venture aps ), a company organized under the laws of denmark, with headquarters at venlighedsvej 1, dk - 2970 hoersholm, denmark ( “ ov ” ). novartis and ov are each referred to individually as a “ license party ” and together as the “ license parties. ” all definitions that are not defined in this amendment shall have the meaning in the license agreement that is being amended by this amendment. recitals whereas, the license parties previously entered into that certain license agreement, dated april 6, 2018, relating to the compound ( tk1258 a. d. a dovitinib ) ; whereas, pursuant the license agreement, ov caused its subsidiary, ov - spv2 aps, a company organized under the laws of denmark now known as allarity therapeutics denmark aps ( “ ov - spv2 ” ), to issue that certain convertible promissory note, attached as exhibit a to the license agreement ( the “ note ” ) ; whereas, in connection with its first annual audit as a nasdaq listed company, it was discovered that under applicable new york law, section 11. 7 of the license agreement would operate to prevent novartis from enforcing the note as a legal obligation of ov - spv2 in the courts of new york from the date of its original issue because ov - spv2 is an “ affiliate ” of ov and the note was not excluded from the liability limitation provisions of section 11. 7 ; and whereas, with the passage of time during which the note was not accounted for as a legal obligation of ov - spv2 under u. s. generally accepted accounting principles and to rectify the situation, the parties now desire to amend section 11